Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with CD20-positive marginal zone lymphoma (a type of slow-growing blood cancer), confirmed by laboratory testing of tissue samples
• People aged 18 or older, of any gender
• People whose marginal zone lymphoma affects the stomach lining and has come back or stopped responding after local treatments such as surgery, radiation, or antibiotic therapy
• People whose marginal zone lymphoma affects areas outside the stomach (non-gastric type) and has come back after local treatment, or people with more advanced disease who have not yet had systemic treatment and meet certain disease activity thresholds set by international guidelines (confirm with trial site)
• People with marginal zone lymphoma affecting the spleen that has come back after local treatment, or untreated people whose spleen is causing significant problems or whose blood counts have dropped to certain low levels (confirm with trial site)
• People with marginal zone lymphoma affecting the lymph nodes that has come back after local treatment, or people with more advanced disease that meets certain activity thresholds set by international guidelines (confirm with trial site)
• People with a reasonable level of general physical functioning, rated 0–2 on a standard scale used by doctors (meaning someone who is fully active up to someone who is up and about more than half the day but cannot do heavy work)
• People with a life expectancy of at least 3 months
• People with adequate bone marrow, liver, and kidney function (except where affected by the lymphoma itself)
• People who are able and willing to follow all study procedures throughout the trial
• People who provide written consent to participate
• Women who are able to become pregnant and agree to use appropriate contraception during treatment and for at least one year after treatment ends; men who agree to abstain from sex or use barrier contraception during the study

Who may not be able to join:

• People whose marginal zone lymphoma has transformed into a faster-growing (high-grade) type of lymphoma
• People whose lymphoma has spread to the central nervous system (brain or spinal cord)
• People who have previously received systemic treatment for this condition, including immunotherapy, chemotherapy, or targeted drug therapies
• People who have previously had a stem cell transplant or an organ/tissue transplant
• People who have had another invasive cancer within the past 3 years that has not been cured or is still being treated (including ongoing hormone therapy for breast or prostate cancer)
• People with serious uncontrolled heart or blood vessel conditions (such as severe heart failure, irregular heartbeat, recent heart attack, stroke, or bleeding in the brain), blood clotting disorders, connective tissue diseases, or severe active infections including active tuberculosis
• People known to have HIV infection, or active hepatitis B or C infection detected by specific blood tests (certain hepatitis B results may be acceptable if virus levels are low — confirm with trial site)
• People who have received a live vaccine within 4 weeks before starting the trial, or who would need to receive one during the trial (including certain flu vaccines)
• People who need ongoing treatment with certain medications that strongly affect the way the body processes a particular type of drug (CYP3A inhibitors or inducers — confirm with trial site)
• People who are unable to swallow capsules, or who have conditions that significantly affect how the gut absorbs medicines, such as malabsorption syndrome, certain weight-loss surgeries, inflammatory bowel disease, or bowel blockage
• People with a psychiatric condition or any other reason that may make it difficult to fully follow the study requirements
• Women who are pregnant or breastfeeding
• People with other serious uncontrolled medical conditions that, in the treating doctor's opinion, would affect safe participation in the study

Important: Always verify eligibility with the trial site directly before applying.